Read the latest WaveData articles, or search through our archive.

Follow us on LinkedIn to keep up to date with WaveData news, articles, insights and analysis

Please use complete words when searching…

Salbutamol Nebuliser Liquid Unit Dose Vials 2.5mg/2.5ml 20 shortage hits hospitals, pharmacies, and surgeries

Salbutamol Nebuliser Liquid Unit Dose Vials 2.5mg/2.5ml 20 shortage hits hospitals, pharmacies, and surgeries

Hospitals have been advised to place urgent orders and not wait for supplies to be exhausted. There is no real alternative to Salbutamol and it’s a critical part of daily medicine and risks serious harm to patience if supply issues are not resolved quickly. The 2.5 mg pack of this critical medicine has been available for just under £2 for a very long period of at least 10 years. However, between June 2017 and July 2018 the average market price fell to £1.40. At this point manufacturers may have decided that this product was not profitable in the long-term and withdrew some of their manufacturing capability.

read more
ADHD Drug Shortages and Methylphenidate long term price trends

ADHD Drug Shortages and Methylphenidate long term price trends

An increase in global demand due to a rapid rise in the number of ADHD diagnoses, manufacturing issues and delays in distribution are the main reasons for the shortages, say the DHSC. But, what about profitability? Is the market still attractive and generating enough profit for manufacturers to encourage them to compete? Charles Joynson, WaveData MD, investigates the long term price trends of Methylphenidate Tabs 10mg 30s.

read more
Pharmacy First and Impetigo

Pharmacy First and Impetigo

The newly launched Pharmacy First scheme includes impetigo in its list of conditions which pharmacies can treat and prescribe for. The main recommended cream for children with impetigo is Mupirocin Ointment Fortunately, this medication is freely available from suppliers for pharmacies to prescribe and dispense, with over eight wholesalers selling it in January.

read more
How to create a shortage…….

How to create a shortage…….

We were chatting about shortages with some peers last week at the HDA conference.  This got us playing devil’s advocate, how would we create a shortage?

Firstly, we’d cut the reimbursement price of a commonly used generic product to a fraction of its former value. That would do the trick quite nicely, provided it was done quickly. It might help if this price cut happened just before the CPHI conference which last year was in late October in Barcelona. This would give manufacturers a chance to take the product off their requirements list and for contract manufacturers to remove it from theirs. Then make another even more drastic cut to the reimbursement price shortly after the conference to make sure that any foolishly optimistic manufacturers took it off their lists and incurred legal costs at the same time.

read more
VPAG and Older Medicines

VPAG and Older Medicines

The Department of Health and Social Care DHSC has for many years being receiving a rebate from the manufacturers of branded prescribed drugs. This is intended to keep a cap on the growth in the medicines bill whilst allowing manufacturers to make sufficient profits to keep them supplying the NHS.

Previous schemes have included PPRS (prescription price regulatory scheme) which ran until the end of 2013 and VPAS (voluntary scheme for branded medicines pricing and access) which ran from 2014 till the end of 2023. These were both voluntary, but there are and were statutory schemes which manufacturers are entered into if they do not wish to join a voluntary scheme.

For the 2024 to 2028 VPAG scheme, medicines are classed as older if there is now more than 12 years since the first marketing authorisation for the active substance. These older medicines have two rebates. The first is the 10% basic rebate, and the second is the % top-up which can be up to 25%. Therefore ‘older medicines’ includes both the originator and follow-on branded generic medicines.

read more
Are generics cheaper in England than the three devolved nations?

Are generics cheaper in England than the three devolved nations?

WaveData’s MD, Charles Joynson looks at generic products sold in England, Scotland, Northern Ireland, and Wales, in August, September and October of this year, focusing in on the top 500 most commonly advertised products. We only included products whihc were available in all four nations for consistency.

read more
Does competition drive lower prices?

Does competition drive lower prices?

Wavedata looked at the average prices of generic products sold to pharmacies and dispensing doctors between August and October 2023 and compared this with the number of price list offers for the same products in the same time period.

read more
Typical and atypical long term pricing after loss of exclusivity

Typical and atypical long term pricing after loss of exclusivity

The first generic versions of Zonisamide Caps 25mg 14 were launched after loss of exclusivity in November 2015. However, in the run-up to this, the prices being offered to pharmacists and dispensing doctors for the brand declined from about £8.00 to about £7.40. This may be because of parallel import competition against the UK brand.

read more
Eplerenone Tabs unstable long term pricing

Eplerenone Tabs unstable long term pricing

Eplerenone Tabs were launched in September 2014 after the loss of exclusivity of Pfizer’s Inspra brand. Eplerenone is one of those products which is subject to regular price bounces, concessions and shortages. Each of the two packs has experienced three price bounces and three concessions over the last 10 years.

read more
Are concessions and shortages caused by the DHSC?

Are concessions and shortages caused by the DHSC?

It would seem sensible to assume that profitable products are less likely to suffer shortages, concessions and price spikes than products where profit is hard to come by. Charles Joynson, WaveData MD, compared the reimbursement price and the average market price for all the products in the English drug tariff over the last 10 years.

read more